Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.
Clinical trial NCT05985187 · UNKNOWN
Trial details
- NCT number
- NCT05985187
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-20
- Primary completion
- 2023-01-08
- Enrollment
- 412
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.